The results demonstrated that combining the developed strategies during electroporation is highly recommended for the transformation of fast-growing rough mycobacteria. Herein, different strategies are presented that successfully address these three limitations and clearly improve the electroporation efficiencies over the current procedures. The focus was on minimizing three well-known and challenging limitations: the mycobacterial restriction-modification systems, which degrade foreign DNA clump formation of electrocompetent cells before electroporation and electrical discharges during pulse delivery, which were reduced by using salt-free DNA solution.
In this study, the smooth and rough morphotypes of Mycobacteroides abscessus and Mycolicibacterium brumae were used to improve current electroporation procedures for fast-growing rough mycobacteria. However, transformation efficiencies differ widely between species and strains. Through this technique, fast- and slow-growing mycobacteria with smooth and rough morphotypes have been successfully transformed. Easily applicable modifications to electroporation conditions improve the transformation efficiency rates for rough morphotypes of fast-growing mycobacteria New Biotechnology 63, 10-18Įlectroporation is the most widely used and efficient method to transform mycobacteria. This approach could potentially be extended to other kinds of diseases by selecting appropriate biomolecules.Ĭampo-Pérez, Víctor, Cendra, Maria del Mar, Julián, Esther, Torrents, Eduard, (2021). This study thus provides a proof-of-concept, demonstrating that enzyme-based nanomotors are capable of fighting infectious diseases. In addition, U-MSNPs in concentrations above 200 μg/mL were capable of successfully reducing 60% of the biofilm biomass of a uropathogenic E. U-MSNPs exhibited the highest bactericidal activity due to biocatalysis of urea into NaHCO3 and NH3, which also propels U-MSNPs. We develop nanomotors consisting of mesoporous silica nanoparticles (MSNPs) that were functionalized with either urease (U-MSNPs), lysozyme (L-MSNPs), or urease and lysozyme (M-MSNPs), and use them against nonpathogenic planktonic Escherichia coli. To alleviate this global health problem, we propose drug-free enzyme-based nanomotors for the treatment of bacterial urinary-tract infections. The low efficacy of current conventional treatments for bacterial infections increases mortality rates worldwide. His current research interests focus on the identification of new antimicrobial therapies and unravel the molecular mechanism underlying the transcripcional regulation of bacterial ribonucleotide reductase genes. In 2012, he obtained a position of Junior Group Leader at the (IBEC). After his Postdoc he received a Ramon y Cajal tenure-track contract (2007) from the Spanish Ministry of Science to return to Spain at the Institute for Bioengineering of Catalonia (IBEC). He then moved in the laboratory of Prof Britt-Marie Sjöberg from the Department of Molecular Biology and Functional Genomics at the Stockholm University in Sweden first as a postdoc and then as a researcher (2004-2007).
S.A, an international company leader in clinical diagnostic reagents belonging to the Werfen group. From 20 he was a researcher at the R&D department at Biokit.
During this time he spend 20 months at Karolinska Institute in Sweden with the supervision of Prof. Eduard Torrents obtained his PhD in microbiology in 2001 from the Science Faculty at the University Autonomous of Barcelona.
0 kommentar(er)
